Apo-A1 as a Biomarker for Bladder Cancer Diagnosis
Author Information
Author(s): Li Hongjie, Li Changying, Wu Huili, Zhang Ting, Wang Jin, Wang Shixin, Chang Jiwu
Primary Institution: HeBei United University
Hypothesis
Can Apo-A1 be used as a biomarker for early diagnosis and classification of bladder transitional cell carcinoma?
Conclusion
Apo-A1 could serve as a potential biomarker for early diagnosis and classification of bladder cancer.
Supporting Evidence
- Apo-A1 levels were significantly higher in urine samples from bladder cancer patients compared to healthy individuals.
- The study identified five proteins, including Apo-A1, that were differentially expressed in bladder cancer.
- Apo-A1 showed a sensitivity of 91.6% and specificity of 85.7% for diagnosing bladder cancer.
Takeaway
This study found that a protein called Apo-A1 in urine can help doctors tell if someone has bladder cancer and how serious it is.
Methodology
Urine samples were analyzed using two-dimensional electrophoresis and mass spectrometry to identify differentially expressed proteins.
Potential Biases
Potential bias in sample selection and the influence of confounding factors on Apo-A1 levels.
Limitations
The study may not account for all variables affecting Apo-A1 levels, such as benign conditions.
Participant Demographics
Included 24 healthy volunteers, 8 with benign bladder conditions, and 40 bladder cancer patients.
Statistical Information
P-Value
p<0.01
Confidence Interval
95% CI 0.870-0.986
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website